Drug Profile
Research programme: VEGF receptor antagonists - AstraZeneca
Alternative Names: AZD 9935Latest Information Update: 13 Feb 2008
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Jan 2008 Discontinued - Preclinical for Solid tumours in United Kingdom (unspecified route)
- 17 Dec 2007 AZD 9935 is still in preclinical trials for Solid tumours in the United Kingdom
- 26 Jul 2006 This programme is still in active development